KEY POINTS
• Administration of plasma to a factor V deficient individual yields a stable platelet factor V/Va pool derived from megakaryocyte endocytosis
•
Platelets and platelet-derived factor V/Va promote and extend hemostasis well after depletion of the plasma-derived factor V pool
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ABSTRACT
Whole genome sequencing of an individual completely devoid of plasma-and platelet-derived factor V (FV) identified 167 variants in his F5 gene including previously identified and damaging missense mutations at rs6027 and Leu90Ser. Since the administration of fresh-frozen plasma (FFP) prevents gastrointestinal bleeding in this individual, its effects on his plasma-and platelet-derived FV concentrations were assessed. The patient's plasma FV levels peaked by two hours following FFP administration and were undetectable 96 hours later. In contrast, increased platelet-derived FV/Va concentrations were observed within six hours, peaked at 24 hours, decreased slowly over two weeks, and originated from megakaryocyte endocytosis and intracellular processing of plasma FV. Ten days after transfusion, no thrombin was generated in a tissue factor-initiated whole blood clotting assay unless exogenous FV was added, consistent with the complete absence of plasma FV. In marked contrast, release of the patient's plateletderived FV/Va (7% of normal) following platelet activation, resulted in robust thrombin generation, similar to that in an individual with normal plasma-and platelet-derived FV concentrations. Thus, total FV deficiency can be corrected by plasma administration, which partially repletes and sustains the platelet cofactor pool, thereby highlighting the critical role of platelet-derived FV/Va in ensuring hemostatic competence. . This platelet-derived FV pool originates solely from megakaryocyte endocytosis of the plasma procofactor through a process which results in the formation of a partially proteolytically-activated cofactor (FV/Va), 4 and phenotypically alters it to a more procoagulant phenotype.
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The most common treatment for individuals with symptomatic FV deficiency is administration of fresh frozen plasma (FFP) to temporarily maintain plasma FV at minimally hemostatic levels (20-30%). 11 Its effect on platelet-derived FV/Va concentrations is unknown. In the current investigation, an individual with undetectable levels of both plasma-and plateletderived FV/Va, 3 who receives FFP transfusions to control gastrointestinal (GI) bleeding, was studied.
MATERIALS & METHODS

Patient history:
A 67-year old male with congenital FV deficiency (<1% plasma-and plateletderived FV antigen and activity) 3 
Western blotting analyses of platelet-and plasma-derived factor V:
Plasma and platelet-derived FV/Va were visualized by western blotting as detailed previously. 9 For quantitative western blotting analyses, platelet lysates 5 were treated with thrombin (2 U/mL, 10 min, 37°C) to convert all platelet-derived FV/Va to FVa. The density of the platelet-derived FVa heavy and light chains were compared to a standard curve prepared from an unaffected control presumed to have ~10,000 3 molecules FV/platelet.
Whole blood coagulation:
Tissue factor (TF)-initiated whole blood clotting assays and quantification of serum thrombin-antithrombin complex (TAT) formation were performed as described. 13 Whole blood clotting reactions contained: 1) TF (5pM) and corn trypsin inhibitor (CTI) (100µg/ml); 2) TF, CTI and FV (2nM); 3) TF, CTI, PARS 1 (100μM) and 4 (500μM); and 4) CTI alone.
Measurement of tissue factor pathway inhibitor (TFPI):
Plasma TFPI was quantified using Quantikine® Human TFPI Immunoassay (R&D Systems, Minneapolis MN, USA).
RESULTS & DISCUSSION
Whole genome sequencing identified 167 variants in the patient's F5 gene. Two variants, rs6027 (A6755G mutation causing an Asp2194Gly substitution in the FV C2 domain) and L90S
[an A to G mutation at chr1:169541563 causing a Leu90Ser (Leu62Ser) substitution in the FV A1 domain], were classified as damaging, having been shown previously to be associated with FV deficiency. 14, 15 The patient is heterozygous at both loci, which may explain his complete absence of FV; however, other variants may play a role.
Following FFP administration, the patient's plasma FV concentration increased from undetectable (t=0 hrs) to 1.3µg/mL (2 hrs) ( Figure 1A , circles), declined rapidly and was undetectable by 96 hours. These data were confirmed by western blotting ( Figure 1B Figure 1A, triangles) . A follow-up study confirmed that the rapid acquisition of FV by the patient's platelets was the result of megakaryocyte and not platelet endocytosis of the plasma molecule (Supplemental Figure 1) , and that following endocytosis, the patient's platelet-derived FV/Va was proteolytically processed normally 4 (Supplemental Figure 2) .
The ability of the patient's platelets and platelet-derived FV/Va to support thrombin generation ten days after FFP administration was assessed in a TF-dependent, contact pathwaysuppressed, whole blood clotting assay 13 following platelet activation with PAR1 and PAR4 peptides (Supplemental Figure 3 ). Simultaneous addition of TF and the agonist peptides had little effect on whole blood clotting and thrombin formation in an unaffected individual (Supplemental Figure 4) . While no thrombin was generated in the absence of added FV ( Figure   2 , closed squares), the simultaneous addition of PAR1 and PAR4 to the patient's blood 
in thrombin generation at the platelet surface. 16 Thus, these combined observations suggest that despite a complete absence of a plasma-derived FV and the presence of ~7% normal levels of platelet-derived FV/Va, the persistence of the highly procoagulant cofactor in the patient's platelets confers hemostatic competence. The importance of platelets and plateletderived FV/Va in sustaining normal hemostasis is supported by several studies. A patient with a neutralizing inhibitor to plasma-but not platelet-derived FV showed no bleeding tendency following extensive surgical challenge. 16 In contrast, individuals with platelet-derived FV/Va inhibitors exhibit severe GI bleeding. 17, 18 Other reports describe the success of platelet transfusions in the cessation of severe bleeding resulting from FV deficiency 19, 20 or FV inhibitors. [21] [22] [23] In a recent study, Duckers et al. described three individuals with severe plasmaderived FV/Va deficiency (<1% activity) but expression of detectable platelet-derived FV/Va antigen and activity (1.7-6.4%) who exhibited only a mild bleeding diathesis. 24 The authors speculate that this residual platelet-derived FV/Va coupled with the decreased TFPI levels observed in these individuals allows for sufficient thrombin generation to prevent fatal bleeding. 24 Indeed, our patient's plasma TFPIα level (5.9±0.65 ng/mL) was dramatically lower than that observed in a normal plasma pool (13.0±0.95 ng/mL) consistent with previous observations made in FV-deficient individuals.
24,25
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From 
